Researchers found that genome-wide plasma cfDNA methylation profiles collected before diagnosis contained early molecular signatures associated with future prostate and breast cancer, with prostate silencer methylation providing the stronger risk stratification. Breast enhancer signals were weaker and varied by subtype and disease stage, indicating that cfDNA methylation may have greater value for risk assessment and surveillance than as a standalone diagnostic test.
More...